Ion Mobility Derived Collision Cross Sections to Support Metabolomics Applications

Citations Over TimeTop 1% of 2014 papers

Abstract

Metabolomics is a rapidly evolving analytical approach in life and health sciences. The structural elucidation of the metabolites of interest remains a major analytical challenge in the metabolomics workflow. Here, we investigate the use of ion mobility as a tool to aid metabolite identification. Ion mobility allows for the measurement of the rotationally averaged collision cross-section (CCS), which gives information about the ionic shape of a molecule in the gas phase. We measured the CCSs of 125 common metabolites using traveling-wave ion mobility-mass spectrometry (TW-IM-MS). CCS measurements were highly reproducible on instruments located in three independent laboratories (RSD < 5% for 99%). We also determined the reproducibility of CCS measurements in various biological matrixes including urine, plasma, platelets, and red blood cells using ultra performance liquid chromatography (UPLC) coupled with TW-IM-MS. The mean RSD was < 2% for 97% of the CCS values, compared to 80% of retention times. Finally, as proof of concept, we used UPLC-TW-IM-MS to compare the cellular metabolome of epithelial and mesenchymal cells, an in vitro model used to study cancer development. Experimentally determined and computationally derived CCS values were used as orthogonal analytical parameters in combination with retention time and accurate mass information to confirm the identity of key metabolites potentially involved in cancer. Thus, our results indicate that adding CCS data to searchable databases and to routine metabolomics workflows will increase the identification confidence compared to traditional analytical approaches.

Related Papers

• → Identification of bioactive metabolites using activity metabolomics(2019)995 cited
• → A metabolomic view of how the human gut microbiota impacts the host metabolome using humanized and gnotobiotic mice(2013)355 cited
• → Microbial metabolomics: Toward a platform with full metabolome coverage(2007)206 cited
• → The use of metabolomics for the discovery of new biomarkers of effect(2007)204 cited
• → Metabolomics: Metabolome measurement in human plasma(2006)